Hannah Gordon is Chief Scientific Officer at Enveda, where she advanced an AI-discovered drug, ENV-294, into clinical trials with reported Phase 1b results. She turns frontier machine learning for drug discovery into therapeutics that reach patients, bridging computational science and clinical development to bring nature-derived, AI-designed medicines toward approval.